We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
We want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. Our ambition is to stop the progress of these often degenerative, debilitating, and life-threatening conditions, achieve remission, and one day cure them.
We are leading a revolution in oncology to redefine cancer care. We have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
Our purpose and values
Our purpose and values help explain why we exist, what we hope to accomplish, the behaviours we value, how we will achieve our goals, and the promise of our brand to our stakeholders.
We push the boundaries of science to deliver life-changing medicines.
Our purpose underpins everything we do. It gives us a reason to come to work every day. It reminds us why we exist as a company. It helps us deliver benefits to patients and create value for shareholders. It also sets the context for our employees’ activities and the roles of our teams, partners and other collaborators.
We follow the science. We put patients first. We play to win. We do the right thing. We are entrepreneurial.
Our values determine how we work together and the behaviours that are integral to our drive for success. Our values guide our decision making, define our beliefs and foster a strong AstraZeneca culture.
News & press releases
Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer
AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial
Enhertu granted Breakthrough Therapy Designation in US for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals